On Tuesday, Atossa Therapeutics Inc (NASDAQ: ATOS) opened lower -5.52% from the last session, before settling in for the closing price of $0.88. Price fluctuations for ATOS have ranged from $0.55 to $1.81 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -26.67% at the time writing. With a float of $129.13 million, this company’s outstanding shares have now reached $129.17 million.
In an organization with 15 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atossa Therapeutics Inc (ATOS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atossa Therapeutics Inc is 0.03%, while institutional ownership is 27.52%. The most recent insider transaction that took place on Mar 26 ’25, was worth 7,000. In this transaction Director of this company bought 10,000 shares at a rate of $0.70, taking the stock ownership to the 10,257 shares.
Atossa Therapeutics Inc (ATOS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -26.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.87% during the next five years compared to 36.92% growth over the previous five years of trading.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Check out the current performance indicators for Atossa Therapeutics Inc (ATOS). In the past quarter, the stock posted a quick ratio of 14.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.20, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.73 million. That was better than the volume of 0.67 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.72%. Additionally, its Average True Range was 0.06.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 37.20%, which indicates a significant decrease from 71.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.27% in the past 14 days, which was higher than the 67.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7157, while its 200-day Moving Average is $1.0964. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $0.9000. Second resistance stands at $0.9700. The third major resistance level sits at $1.0200. If the price goes on to break the first support level at $0.7800, it is likely to go to the next support level at $0.7300. Assuming the price breaks the second support level, the third support level stands at $0.6600.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
There are currently 129,170K shares outstanding in the company with a market cap of 107.36 million. Presently, the company’s annual sales total 0 K according to its annual income of -25,500 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,350 K.
